These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 7884290

  • 1. Does tirapazamine (SR-4233) have any cytotoxic or sensitizing effect on three human tumour cell lines at clinically relevant partial oxygen pressure?
    Lartigau E, Guichard M.
    Int J Radiat Biol; 1995 Feb; 67(2):211-6. PubMed ID: 7884290
    [Abstract] [Full Text] [Related]

  • 2. [In vitro oxygen-dependent survival of 2 human cell lines after radiation combined with tirapazamine (SR-4233) and cisplatin].
    Lartigau E, Stern S, Guichard M.
    Cancer Radiother; 2000 Feb; 4(3):217-22. PubMed ID: 10897765
    [Abstract] [Full Text] [Related]

  • 3. The effect of the hypoxic cell drug SR-4233 alone or combined with the ionizing radiations on two human tumor cell lines having different radiosensitivity.
    Lambin P, Guichard M, Chavaudra N, Malaise EP.
    Radiother Oncol; 1992 Jul; 24(3):201-4. PubMed ID: 1410575
    [Abstract] [Full Text] [Related]

  • 4. Effect of radiation and tirapazamine (SR-4233) on three melanoma cell lines.
    Zhang M, Stevens G.
    Melanoma Res; 1998 Dec; 8(6):510-5. PubMed ID: 9918413
    [Abstract] [Full Text] [Related]

  • 5. Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069.
    Patterson AV, Saunders MP, Chinje EC, Talbot DC, Harris AL, Strafford IJ.
    Br J Cancer; 1997 Dec; 76(10):1338-47. PubMed ID: 9374381
    [Abstract] [Full Text] [Related]

  • 6. The effect of tirapazamine (SR-4233) alone or combined with chemotherapeutic agents on xenografted human tumours.
    Lartigau E, Guichard M.
    Br J Cancer; 1996 Jun; 73(12):1480-5. PubMed ID: 8664116
    [Abstract] [Full Text] [Related]

  • 7. Measurement of delivery and metabolism of tirapazamine to tumour tissue using the multilayered cell culture model.
    Kyle AH, Minchinton AI.
    Cancer Chemother Pharmacol; 1999 Jun; 43(3):213-20. PubMed ID: 9923551
    [Abstract] [Full Text] [Related]

  • 8. Nicotinamide and carbogen: relationship between pO2 and radiosensitivity in three tumour lines.
    Martin LM, Thomas CD, Guichard M.
    Int J Radiat Biol; 1994 Mar; 65(3):379-86. PubMed ID: 7908317
    [Abstract] [Full Text] [Related]

  • 9. Oxygen dependence of the metabolic activation and cytotoxicity of tirapazamine: implications for extravascular transport and activity in tumors.
    Hicks KO, Siim BG, Pruijn FB, Wilson WR.
    Radiat Res; 2004 Jun; 161(6):656-66. PubMed ID: 15161354
    [Abstract] [Full Text] [Related]

  • 10. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.
    Brown JM.
    Br J Cancer; 1993 Jun; 67(6):1163-70. PubMed ID: 8512801
    [Abstract] [Full Text] [Related]

  • 11. Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine.
    Hicks KO, Myint H, Patterson AV, Pruijn FB, Siim BG, Patel K, Wilson WR.
    Int J Radiat Oncol Biol Phys; 2007 Oct 01; 69(2):560-71. PubMed ID: 17869669
    [Abstract] [Full Text] [Related]

  • 12. Tirapazamine: hypoxic cytotoxicity and interaction with radiation as assessed by the micronucleus assay.
    Shibata T, Shibamoto Y, Sasai K, Oya N, Murata R, Takagi T, Hiraoka M, Takahashi M, Abe M.
    Br J Cancer Suppl; 1996 Jul 01; 27():S61-4. PubMed ID: 8763848
    [Abstract] [Full Text] [Related]

  • 13. SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells.
    Zeman EM, Brown JM, Lemmon MJ, Hirst VK, Lee WW.
    Int J Radiat Oncol Biol Phys; 1986 Jul 01; 12(7):1239-42. PubMed ID: 3744945
    [Abstract] [Full Text] [Related]

  • 14. Aerobic radiosensitization by SR 4233 in rodent and human cells: mechanistic and therapeutic implications.
    Zeman EM, Brown JM.
    Int J Radiat Biol; 1991 Jan 01; 59(1):117-31. PubMed ID: 1671059
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of agents counteracting hypoxia in fractionated radiation regimes.
    Stern S, Guichard M.
    Radiother Oncol; 1996 Nov 01; 41(2):143-9. PubMed ID: 9004358
    [Abstract] [Full Text] [Related]

  • 16. In vitro activity of the benzotriazine dioxide SR 4233 against human tumour colony-forming units.
    Hanauske AR, Ross M, Degen D, Hilsenbeck SG, Von Hoff DD.
    Eur J Cancer; 1993 Nov 01; 29A(3):423-5. PubMed ID: 8398345
    [Abstract] [Full Text] [Related]

  • 17. The role of DT-diaphorase in determining the sensitivity of human tumor cells to tirapazamine (SR 4233).
    Patterson AV, Robertson N, Houlbrook S, Stephens MA, Adams GE, Harris AL, Stratford IJ, Carmichael J.
    Int J Radiat Oncol Biol Phys; 1994 May 15; 29(2):369-72. PubMed ID: 8195035
    [Abstract] [Full Text] [Related]

  • 18. Tirapazamine-induced DNA damage measured using the comet assay correlates with cytotoxicity towards hypoxic tumour cells in vitro.
    Siim BG, van Zijl PL, Brown JM.
    Br J Cancer; 1996 Apr 15; 73(8):952-60. PubMed ID: 8611431
    [Abstract] [Full Text] [Related]

  • 19. SR 4233: a tumor specific radiosensitizer active in fractionated radiation regimes.
    Brown JM, Lemmon MJ.
    Radiother Oncol; 1991 Apr 15; 20 Suppl 1():151-6. PubMed ID: 2020764
    [Abstract] [Full Text] [Related]

  • 20. Enhancement of radiation-induced tumor cell killing by the hypoxic cell toxin SR 4233.
    Zeman EM, Hirst VK, Lemmon MJ, Brown JM.
    Radiother Oncol; 1988 Jul 15; 12(3):209-18. PubMed ID: 3175048
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.